DUBLIN, Nov. 15,
2023 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will participate in a Fireside Chat at the
6th Annual Evercore ISI HealthCONx
Conference Tuesday, November 28 at
1:45 pm EST (10:45 am PST/6:45 pm
GMT) and will be hosting in-person meetings with the
investment community at the conference.
A Webcast of the event may be accessed by visiting
Theravance.com, under the Investors section: Presentations and
Events. A Replay of the webcast will be archived on the Company's
website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to
deliver Medicines that Make a
Difference® in people's lives. In pursuit of
its purpose, Theravance Biopharma leverages decades of
expertise, which has led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution
indicated for the maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage
investigational norepinephrine reuptake inhibitor in development
for symptomatic neurogenic orthostatic hypotension, has the
potential to be a first in class therapy effective in treating a
constellation of cardinal symptoms in multiple symptom atrophy
patients. The Company is committed to creating/driving shareholder
value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of
the Theravance Biopharma group of companies (in
the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris company. Trademarks, trade names or
service marks of other companies appearing on this press release
are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference-301988516.html
SOURCE THERAVANCE BIOPHARMA US, INC.